Objective Hepatocellular carcinoma(HCC)is one of the most common malignancies and lethal neoplasm worldwide with rapidly increasing incidence.Sorafenib was firstly approved for the treatment of advanc
Objective To investigate the efficacy and safety of single-or double-drug cytotoxic regimens as second-line treatment of advanced gastric cancer,and to figure the potential predictive factors associat
Objective Hepatocellular carcinoma(HCC),which is considered as the most common primary liver malignancy in China,ranks the third among the causes of cancer mortality.